Variables
|
High-dose of RSV n/population (%)
|
Control n/population (%)
|
---|
Number of patients
|
1671/3273 (51.1 %)
|
1602/3273 (48.9 %)
|
Male
|
1150/1671 (68.8 %)
|
1075/1602 (67.1 %)
|
Hypertension
|
1088/1671 (65.1 %)
|
988/1602 (61.7 %)
|
Diabetes Mellitus
|
473/1671 (28.3 %)
|
449/1602 (28.0 %)
|
Smoker
|
592/1606 (36.9 %)
|
573/1542 (37.2 %)
|
Previous MI
|
223/1067 (20.9 %)
|
224/1069 (21.0 %)
|
Previous PCI
|
160/1019 (15.7 %)
|
143/1017 (14.1 %)
|
Stable angina
|
732/1671 (43.8 %)
|
657/1602 (41.0 %)
|
NSTEMI
|
759/1671 (45.4 %)
|
759/1602 (47.3 %)
|
STEMI
|
181/1671 (10.8 %)
|
188/1602 (11.7 %)
|
Multi-vessel disease
|
198/644 (30.7 %)
|
157/633 (24.8 %)
|
B2/C lesions
|
654/918 (71.2 %)
|
590/855 (69.0 %)
|
Thrombus
|
122/757 (16.1 %)
|
135/763 (17.7 %)
|
LM
|
16/700 (2.3 %)
|
25/709 (3.5 %)
|
LAD
|
666/1253 (53.2 %)
|
619/1174 (52.7 %)
|
LCX
|
360/1315 (27.3 %)
|
354/1244 (28.4 %)
|
RCA
|
393/1253 (31.4 %)
|
368/1174 (31.3 %)
|
Multiple vessel PCI
|
216/644 (33.5 %)
|
203/768 (26.4 %)
|
Aspirin
|
1624/1671 (97.2 %)
|
1548/1602 (96.6 %)
|
Clopidogrel
|
1599/1605 (99.6 %)
|
1530/1536 (99.6 %)
|
β-blockers
|
952/1393 (68.3 %)
|
979/1402 (69.8 %)
|
ACEI/ARB
|
910/1393 (65.3 %)
|
953/1402 (67.9 %)
|
Glycoprotein IIb/IIIa inhibitors
|
76/1025 (7.4 %)
|
103/959 (10.7 %)
|
Numbers of DES
|
560/696 (80.5 %)
|
556/691 (80.5 %)
|
-
Previous MI previous myocardial infarction, Previous PCI previous percutaneous coronary intervention, NSTE-ACS non-ST segment elevation acute coronary syndrome, STEMI ST segment elevation myocardial infarction, LM, left main, LAD left anterior descending, LCX left circumflex, RCA right coronary artery, DES drug-eluting stent